References
- Steffes MW, Sibley S, Jackson M, Thomas W. Beta-cell function and the development of diabetes-related complications in the Diabetes Control and Complications Trial. Diabetes Care 26(3), 832–836 (2003).
- Wahren J, Ekberg K, Jörnvall H. C-peptide is a bioactive peptide. Diabetologia 50(3), 503–509 (2007).
- Gonez LJ, Knight KR. Cell therapy for diabetes: stem cells, progenitors or beta-cell replication? Mol. Cell Endocrinol. 323(1), 55–61 (2010).
- Herold KC, Gitelman SE, Masharani U et al. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of Type 1 diabetes. Diabetes 54, 1763–1769 (2005).
- Keymeulen B, Vandemeulebroucke E, Ziegler AG et al. Insulin needs after CD3-antibody therapy in new-onset Type 1 diabetes. N. Engl. J. Med. 352, 2598–2608 (2005).
- Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H et al. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N. Engl. J. Med. 361(22), 2143–2152 (2009).
- Sherry N, Hagopian W, Ludvigsson J et al. Teplizumab for treatment of Type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial. Lancet 378(9790), 487–497 (2011).
- Gottlieb PA, Pozzilli P. DEFEND. Presented during session: Treatment of Type 1 diabetes – update on clinical trials. Presented at: ADA 71st Scientific Sessions. San Diego, CA, USA, 28 June 2011.
- Näntö-Salonen K, Kupila A, Simell S et al. Nasal insulin to prevent Type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial. Lancet 372(9651), 1746–1755 (2008).
- Vehik K, Cuthbertson D, Ruhlig H, Schatz DA, Peakman M, Krischer JP; DPT-1 and TrialNet Study Groups. Long-term outcome of individuals treated with oral insulin: diabetes prevention trial-Type 1 (DPT-1) oral insulin trial. Diabetes Care 34(7), 1585–1590 (2011).
- Raz I, Elias D, Avron A, Tamir M, Metzger M, Cohen IR. Beta-cell function in new-onset Type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, Phase II trial. Lancet 358, 1749–1753 (2001).
- Schloot NC, Meierhoff G, Lengyel C et al. Effect of heat shock protein peptide DiaPep277 on beta-cell function in paediatric and adult patients with recent-onset diabetes mellitus Type 1: two prospective, randomized, double-blind Phase II trials. Diabetes Metab. Res. Rev. 23(4), 276–285 (2007).
- Ludvigsson J, Faresjö M, Hjorth M et al. GAD treatment and insulin secretion in recent-onset Type 1 diabetes. N. Engl. J. Med. 359(18), 1909–1920 (2008).
- Ludvigsson J, Hjorth M, Chéramy M et al. Extended evaluation of the safety and efficacy of GAD treatment of children and adolescents with recent-onset Type 1 diabetes: a randomised controlled trial. Diabetologia 54(3), 634–640 (2011).
- Wherrett DK, Bundy B, Becker DJ et al. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset Type 1 diabetes: a randomised double-blind trial. Lancet 378(9788), 319–327 (2011).
- Ludvigsson J, Krisky D, Casas R et al. GAD65 antigen therapy in recently diagnosed Type 1 diabetes mellitus. Presented at: ADA 71st Scientific Sessions. San Diego, CA, USA, 28 June 2011.
- Huurman VA, van der Meide PE, Duinkerken G et al. Immunological efficacy of heat shock protein 60 peptide DiaPep277 therapy in clinical Type I diabetes. Clin. Exp. Immunol. 152(3), 488–497 (2008).
- Song HY, Abad MM, Mahoney CP, McEvoy RC. Human insulin B chain but not A chain decreases the rate of diabetes in BB rats. Diabetes Res. Clin. Pract. 46(2), 109–114 (1999).
- von Herrath MG, Whitton JL. DNA vaccination to treat autoimmune diabetes. Ann. Med. 32(5), 285–292 (2000).
- Jun HS, Chung YH, Han J et al. Prevention of autoimmune diabetes by immunogene therapy using recombinant vaccinia virus expressing glutamic acid decarboxylase. Diabetologia 45(5), 668–676 (2002).